Tolerability of everolimus-based immunosuppression in maintenance liver transplant recipients

Clinical Transplantation

Volumn 25, Issue 4, 2011, Pages 660-669

  Vallin, Mélanie ^a   Guillaud, Olivier ^a   Morard, Isabelle ^b   Gagnieu, Marie Claude ^a   Mentha, Gilles ^b   Adham, Mustapha ^a   Morelon, Emmanuel ^a   Boillot, Olivier ^a   Giostra, Emiliano ^b   Dumortier, Jérôme ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Immunosuppression; Liver transplantation; MTOR inhibitors; Rejection; Tolerability

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ANEMIA; ARTICLE; BLOOD TOXICITY; DERMATITIS; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LYMPHATIC SYSTEM DISEASE; LYMPHORRHEA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; PANCYTOPENIA; PRIORITY JOURNAL; PROTEINURIA; UNSPECIFIED SIDE EFFECT;

CALCINEURIN; COHORT STUDIES; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; SIROLIMUS; SURVIVAL RATE; TACROLIMUS; TREATMENT OUTCOME;

EID: 80051696782     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01370.x     Document Type: Article

References (59)

1. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008: 371: 838.
2. Conti F, Morelon E, Calmus Y. Immunosuppressive therapy in liver transplantation. J Hepatol 2003: 39: 664.
3. Sheiner PA, Magliocca JF, Bodian CA et al. Long-term medical complications in patients surviving > or = 5years after liver transplant. Transplantation 2000: 69: 781.
4. Neff GW, Montalbano M, Slapak-Green G et al. Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency. Transplant Proc 2003: 35: 3029.
5. Formica RN Jr, Lorber KM, Friedman AL et al. The evolving experience using everolimus in clinical transplantation. Transplant Proc 2004: 36: 495S.
6. Nashan B, Curtis J, Ponticelli C et al. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 2004: 78: 1332.
7. Kovarik JM. Everolimus: a proliferation signal inhibitor targeting primary causes of allograft dysfunction. Drugs Today (Barc) 2004: 40: 101.
8. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008: 372: 449.
9. Chollet P, Abrial C, Tacca O et al. Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer. Clin Breast Cancer 2006: 7: 336.
10. Coiffier B, Ribrag V. Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies. Leuk Lymphoma 2009: 50: 1916.
11. Buell JF, Brock GN. Risk of cancer in liver transplant recipients: a look into the mirror. Liver Transpl 2008: 14: 1561.
12. Levy GA, Grant D, Paradis K et al. Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients. Transplantation 2001: 71: 160.
13. Levy G, Schmidli H, Punch J et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 2006: 12: 1640.
14. Sanchez EQ, Martin AP, Ikegami T et al. Sirolimus conversion after liver transplantation: improvement in measured glomerular filtration rate after 2years. Transplant Proc 2005: 37: 4416.
15. Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 2002: 11: 1845.
16. Lorber MI, Mulgaonkar S, Butt KM et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005: 80: 244.
17. Vitko S, Margreiter R, Weimar W et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005: 5: 2521.
18. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003: 349: 847.
19. Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 2003: 35: 52S.
20. Kreis H, Oberbauer R, Campistol JM et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004: 15: 809.
21. Morard I, Dumortier J, Spahr L et al. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients. Liver Transpl 2007: 13: 658.
22. Fairbanks KD, Eustace JA, Fine D et al. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003: 9: 1079.
23. Jensen GS, Wiseman A, Trotter JF. Sirolimus conversion for renal preservation in liver transplantation: not so fast. Liver Transpl 2008: 14: 601.
24. DuBay D, Smith RJ, Qiu KG et al. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens. Liver Transpl 2008: 14: 651.
25. Shenoy S, Hardinger KL, Crippin J et al. Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial. Transplantation 2007: 83: 1389.
26. Campbell MS, Rai J, Kozin E et al. Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation. Clin Transplant 2007: 21: 377.
27. Davies DR, Bittmann I, Pardo J. Histopathology of calcineurin inhibitor-induced nephrotoxicity. Transplantation 2000: 69: SS11.
28. Campistol JM, Sacks SH. Mechanisms of nephrotoxicity. Transplantation 2000: 69: SS5.
29. Vitko S, Tedesco H, Eris J et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004: 4: 626.
30. Fiocchi R, Iacovoni A, Sebastiani R et al. Possible role of everolimus in improving renal function in long-term heart transplantation. Transplant Proc 2007: 39: 1967.
31. De Simone P, Metselaar HJ, Fischer L et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl 2009: 15: 1262.
32. De Simone P, Precisi A, Petruccelli S et al. The impact of everolimus on renal function in maintenance liver transplantation. Transplant Proc 2009: 41: 1300.
33. Chapman JR, Valantine H, Albanell J et al. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc 2007: 39: 2937.
34. Straathof-Galema L, Wetzels JF, Dijkman HB et al. Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism. Am J Transplant 2006: 6: 429.
35. Fernandez-Fresnedo G, Plaza JJ, Sanchez-Plumed J et al. Proteinuria: a new marker of long-term graft and patient survival in kidney transplantation. Nephrol Dial Transplant 2004: 19(Suppl 3): iii47.
36. Dittrich E, Schmaldienst S, Soleiman A et al. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 2004: 17: 215.
37. Letavernier E, Legendre C. mToR inhibitors-induced proteinuria: mechanisms, significance, and management. Transplant Rev (Orlando) 2008: 22: 125.
38. Lynn M, Abreo K, Zibari G et al. End-stage renal disease in liver transplants. Clin Transplant 2001: 15(Suppl 6): 66.
39. Dervaux T, Caillard S, Meyer C et al. Is sirolimus responsible for proteinuria? Transplant Proc 2005: 37: 2828.
40. Jindal RM, Hughes D, Sidner RA et al. Proteinuria in recipients of liver transplants. Clin Transplant 1996: 10: 39.
41. Seeliger H, Guba M, Kleespies A et al. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev 2007: 26: 611.
42. Gutierrez-Dalmau A, Campistol JM. The role of proliferation signal inhibitors in post-transplant malignancies. Nephrol Dial Transplant 2007: 22(Suppl 1): i11.
43. Bilbao I, Sapisochin G, Dopazo C et al. Indications and management of everolimus after liver transplantation. Transplant Proc 2009: 41: 2172.
44. Campistol JM, Eris J, Oberbauer R et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006: 17: 581.
45. Kauffman HM, Cherikh WS, Cheng Y et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005: 80: 883.
46. Dumortier J, Guillaud O, Adham M et al. Negative impact of de novo malignancies rather than alcohol relapse on survival after liver transplantation for alcoholic cirrhosis: a retrospective analysis of 305 patients in a single center. Am J Gastroenterol 2007: 102: 1032.
47. Stippel DL, Kasper HU, Schleimer K et al. Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation. Transplant Proc 2005: 37: 2185.
48. Elsharkawi M, Staib L, Henne-Bruns D et al. Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation 2005: 79: 855.
49. De Fijter JW. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation. Nephrol Dial Transplant 2007: 22(Suppl 1): i23.
50. Gomez-Camarero J, Salcedo M, Rincon D et al. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation 2007: 84: 786.
51. Tenderich G, Fuchs U, Zittermann A et al. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients. Clin Transplant 2007: 21: 536.
52. Masetti M, Rompianesi G, Montalti R et al. Effects of everolimus monotherapy on hematological parameters and iron homeostasis in de novo liver transplant recipients: preliminary results. Transplant Proc 2008: 40: 1947.
53. Sanchez Fructuoso A, Calvo N, Moreno MA et al. Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients. Transplant Proc 2007: 39: 2242.
54. Mahe E, Morelon E, Lechaton S et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005: 79: 476.
55. Mahe E, Morelon E, Lechaton S et al. Acne in recipients of renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and pathogenic aspects. J Am Acad Dermatol 2006: 55: 139.
56. Mabasa VH, Ensom MH. The role of therapeutic monitoring of everolimus in solid organ transplantation. Ther Drug Monit 2005: 27: 666.
57. Augustine JJ, Hricik DE. Experience with everolimus. Transplant Proc 2004: 36: 500S.
58. Kovarik JM, Kaplan B, Tedesco Silva H et al. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation 2002: 73: 920.
59. Alamo JM, Barrera L, Casado MD et al. Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation. Transplant Proc 2009: 41: 2181.